ABOUT CENCORA PHARMALEX
Beginning in January 2024, companies in the PharmaLex family started a journey of rebranding aligned with Cencora, our parent company and a leading global pharmaceutical solutions organization centered on improving lives around the world.
PharmaLex adds to Cencora’s expanding suite of pharma solutions and serves the pharma, biotech, and medtech industries. We guide clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-elevated solutions to support clients through the entire product lifecycle.
View our content to discover how our expanded capabilities can help you – or contact a Cencora PharmaLex expert today with any questions.
CONTACT INFORMATION
Cencora PharmaLex
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
GET MORE DETAILS ON OUR SOLUTIONS
-
![GettyImages-891264822 planning, meeting]( "The Benefits Of Engaging In Pre-Approval Information Exchange (PIE)")
Explore the top 3 insights on the impact of pre-approval communication and learn why healthcare decision makers want more pre-approval resources and engagement from manufacturers.
FEATURED INSIGHTS
-
![Global networking healthcare-GettyImages-1477437266]( "Evolving And Expanding Global Consulting With Local Expertise")
Experts discuss global market expansion, emphasizing regulatory complexities, product lifecycle investments, and integrating local expertise to ensure successful product launches and long-term market sustainability.
-
![compliance GettyImages-1145941803]( "Legal Changes To Fortify Environmental Risk Assessment Of Pharmaceuticals")
A new EU directive may require stricter environmental risk assessments for pharmaceuticals, impacting marketing authorization. Updated guidelines already in effect pose new challenges for companies.
-
![1456216634-digital-pathway]( "The Digital Pharmaceutical Journey: 2025 And Beyond")
By 2025 and beyond, AI, structured data, and real-world evidence will reshape the landscape, driving personalized medicine and more efficient processes. Here are eight key trends to watch.
EXPLORE OUR THOUGHT LEADERSHIP
Explore the latest insights from the Cencora team.
WEBINARS
-
![Brain AI Artificial intelligence-GettyImages-1582604385]( "Harnessing The Power Of AI In Health Evidence Generation Strategy")
Harnessing The Power Of AI In Health Evidence Generation StrategyExplore applications and limitations for artificial intelligence (AI) in healthcare as decision-makers determine whether to adopt the software in their environments.
-
![Preparing For Success]( "How To Ensure A Successful Health Authority Inspection")
How To Ensure A Successful Health Authority InspectionDiscover how to proactively prepare for successful Health Authority Inspections. Learn key strategies and post-inspection activities for regulatory compliance.
-
![Cencora - ATMP webinar Q&A]( "Q&A Interview: Navigating The Launch Of ATMPs In Europe")
Q&A Interview: Navigating The Launch Of ATMPs In EuropeDive into this overview of the evolving regulatory landscape and better understand the importance of proactive planning, collaboration, and expert guidance in navigating the ATMPs ecosystem in Europe.
WHITE PAPERS
-
![GettyImages-1016958284 biosimilar lab]( "20 Years Of Biosimilars: Are We On The Right Track?")
20 Years Of Biosimilars: Are We On The Right Track?Explore the transformative journey of biosimilars, 20 years in. Through industry expert insights collected from a recent panel discussion, explore regulatory hurdles, market shifts, and the path ahead.
PODCASTS
-
![Digital-marketing-GettyImages-1051659276]( "Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty Pharmacy")
Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty PharmacyTune in as experts discuss how biopharma companies can effectively engage healthcare decision-makers in the evolving digital landscape.
-
![Cencora PharmaLex - PlX talks 30]( "An Overview Of Contamination Control Strategy (CCS)")
An Overview Of Contamination Control Strategy (CCS)Join experts Londa Ritchey and Patrick Nieuwenhuizen as they explore the key role of a contamination control strategy in Annex 1 for ensuring patient safety and continuous manufacturing improvement.
-
![Cencora - PharmaLex Talks 27]( "Assessing Gaps And Achieving Compliance With Annex 1")
Assessing Gaps And Achieving Compliance With Annex 1In this podcast episode on Annex 1 compliance and gap assessment, Patrick Nieuwenhuizen shares his insights and expertise gleaned from extensive experience in pharmaceutical regulation and compliance.
